Under the pact, Kinaxo will make use of high-end mass spectrometry-based technologies to quantitatively evaluate posttranslational protein modifications on a proteome-wide scale.
Kinaxo CTO Henrik Daub said that Posttranslational modifications and their regulation are key factors in understanding cellular behavior and molecular drug action.
"We are delighted to apply our expertise to support AstraZeneca‘s research in such highly promising fields of investigation," Daub said.